APOA1 and hyperlipidemia: Liu et al. [48] found that there was a significant reduction in TC, LDL-C, and APOB levels after 12 weeks of pravastatin therapy only among Chinese hyperlipidemia patients expressing the APOA1 (G75A) AA and GA genotypes.